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Abstract: Taxanes are chemotherapeutic agents with a large spectrum of antitumor activity when 
used as monotherapy or in combination regimens. Paclitaxel and docetaxel have poor solubility 
and require a complex solvent system for their commercial formulation, Cremophor EL® (CrEL) 
and Tween 80® respectively. Both these biological surfactants have recently been implicated 
as contributing not only to the hypersensitivity reactions, but also to the degree of peripheral 
neurotoxicity and myelosuppression, and may antagonize the cytotoxicity. Nab-paclitaxel, or 
nanoparticle albumin-bound paclitaxel (ABI-007; Abraxane®), is a novel formulation of paclitaxel 
that does not employ the CrEL solvent system. Nab-paclitaxel demonstrates greater efficacy and 
a favorable safety profile compared with standard paclitaxel in patients with advanced disease 
(breast cancer, non-small cell lung cancer, melanoma, ovarian cancer). Clinical studies in breast 
cancer have shown that nab-paclitaxel is significantly more effective than standard paclitaxel 
in terms of overall objective response rate (ORR) and time to progression. Nab-paclitaxel in 
combination with gemcitabine, capecitabine or bevacizumab has been shown to be very active 
in patients with advanced breast cancer. An economic analysis showed that nab-paclitaxel would 
be an economically reasonable alternative to docetaxel or standard paclitaxel in metastatic breast 
cancer. Favorable tumor ORR and manageable toxicities have been reported for nab-paclitaxel 
as monotherapy or in combination treatment in advanced breast cancer.
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Introduction
Taxanes have had an important influence on the treatment of a wide variety of cancers.1 
The issue of efficacy has been evaluated with both paclitaxel and docetaxel. They are 
approved in many countries for the treatment of breast cancer, ovarian cancer, non-
small cell lung cancer (NSCLC) and prostate cancer. These drugs can be given in a 
variety of schedules and can be combined with other drugs.
Paclitaxel has a poor solubility and requires a complex solvent system for its 
commercial formulation. Cremophor EL® (CrEL), a polyoxyethylated castor vehicle 
and dehydrated ethanol USP, was identified as the best option for the solvent system 
of paclitaxel.2
Docetaxel is a semisynthetic compound produced from 10-deacetylbaccatin-III, which 
is found in the needles of the European yew three, Taxus baccata.3 Docetaxel is more 
water soluble than paclitaxel, but requires equally complex solvent systems.4 For clinical 
use it is solubilized in a polyoxyethylated surfactant, polysorbate 80 (Tween 80®).
The surfactants used in paclitaxel and docetaxel are biologically and pharmacologi-
cally active. A large number of biological effects have been reported in the literature OncoTargets and Therapy 2009:2 180
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on the use of taxanes, such as hypersensitivity reactions and 
peripheral neuropathies. Furthermore, several researchers 
have reported that these solvents modify the pharmacokinetic 
profiles of both drugs. Winner et al showed that a dose esca-
lation of paclitaxel standard formulation increased toxicity, 
but without an increase of activity.5 Paclitaxel has pseudo-
nonlinear plasma pharmacokinetics that depend exclusively 
on CrEL.6 A reduction of clearance and a sequential high 
concentration of paclitaxel place the patients at risk for severe 
toxicity. The CrEL micelles may entrap other hydrophobic 
drugs (eg, doxorubicin) or inhibit drug uptake in the plasma 
(eg, cisplatin). 7
CrEL, which is the vehicle for paclitaxel, has recently 
been implicated as contributing not only to the associated 
neuropathy, but also to the degree of myelosuppression, and 
may attenuate the effects of paclitaxel by causing micelle 
formation around the drug, which decreases the amount of 
the drug that can enter into the tumor cells.2,7,8–11
Polyethylated castor oil is believed to contribute to 
taxane-associated myelosuppression by inhibiting multi-drug 
resistance P-glycoprotein (MDR-P-GP) in hematopoietic 
progenitor cells.12 Polyethylated castor oil has a low distribu-
tion volume and remains within the vasculature compartment 
in continuous contact with bone marrow and may enhance 
myelosuppression, while having a lesser effect on MDR1 
in tumor tissue.
Sensory and motor neuropathy are well-recognized 
toxicities of CrEL taxanes although whether CrEL is the 
sole cause of this toxicity remains unknown.13 Electrophysi-
ologic studies in patients treated with paclitaxel have shown 
evidence of both axonal degeneration and demyelination.14 
Administration of intravenous cyclosporine, which contains 
CrEL in its formulation, results in development of periph-
eral neuropathies in 25% of patients.15 The oral formulation 
of cyclosporine does not induce peripheral neurotoxicity, 
because the CrEL is not absorbed through the gastroin-
testinal tract. CrEL plasma concentrations achieved after 
administration of intravenous paclitaxel and cyclosporine 
have been shown to produce axonal swelling, vesicular 
degeneration and demyelinization in rat dorsal root ganglion 
neurons exposed to the formulation vehicle.16–18 Although 
sensory neuropathies have been associated with CrEL, the 
mechanism of taxane-induced neuropathy may be multi-
factorial.
A recent study has indicated that unsaturated fatty acids 
may cause neurotoxicity, possibly due to the appearance 
of peroxidation products,19 suggesting that the ethoxylated 
derivatives of castor oil probably account for most of the 
neuronal damage in addition to the presence of residual 
ethylene oxide residues.
Similarly, Tween 80, the vehicle for docetaxel, has also 
been implicated in some of the side effects.20
Docetaxel produces a mild and predominantly sensory 
neuropathy in a high proportion of treated patients.21 Treat-
ment with steroids does not prevent docetaxel induced 
neuropathy.22 This effect depends upon the polyethylene 
substitutions produced by reaction of the polyol compound 
with ethylene oxide, even if etoposide that contains Tween 
80 does not induce neuropathy.23,24
Moreover, when either of these drugs is administered, 
premedication with steroids is mandatory. This is a further 
disadvantage, because of patient convenience and because 
there are consequences after using steroids. Finally, there 
are hypersensitivity reactions associated with both drugs 
that can also be fatal. Consequently, those are some of the 
disadvantages associated with both drugs.
To reduce the potential disadvantages of paclitaxel and 
docetaxel, a number of novel taxanes are currently being 
developed. One of these new taxanes is nab-paclitaxel 
(Abraxane®; Abraxis Bioscience), or nanoparticle albumin-
bound paclitaxel.
Pharmacokinetics  
and pharmacodynamics
Nab-paclitaxel is prepared by high-pressure homogenization 
of paclitaxel in the presence of serum albumin, resulting in a 
nanoparticle colloidal suspension.25 These particles have an 
average size of approximately 130 to 150 nm, approximately 
one-hundredth the size of a single red blood cell, and do not 
have the risk of capillary blockage concentration.
Sparreboon et al studied in a comparative preclinical 
and clinical study the pharmacokinetics of nab-paclitaxel 
and CrEL paclitaxel.26 Using a dose of 260 mg/m2 and 
175 mg/m2 of nab-paclitaxel and CrEL paclitaxel, the half-life 
was 21.6 hours and 20.5 hours, respectively, while the areas 
under curve (AUC) were similar despite the different dose. 
Nab-paclitaxel had significantly higher plasma clearance 
and volume distribution. Disappearance from the blood is 
bi-phasic. The different pharmacokinetics of nab-paclitaxel 
reflects the entrapment absence of CrEL-paclitaxel in 
micelles, which are the principal carriers of paclitaxel in the 
systemic circulation.
When ABI-007 circulates, the particles are taken up 
through the endothelial wall, which is facilitated not only 
through leaky vessels but also through albondin (gp60), or 
an albumin receptor. Preclinical work has demonstrated that OncoTargets and Therapy 2009:2 181
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there is preferential uptake of nab-paclitaxel in the tumor 
tissue as opposed to paclitaxel. The albondin receptors 
transport albumin-bound drugs in exactly same way as does 
normal albumin.27 Albumin-bound macromolecules can leave 
the circulation through the leaky tumor microvasculature 
and accumulate in the interstitium because of the enhanced 
permeation and retention effects that are characteristic of 
neoplasia. In addition, albumin is actively transported across 
micro-vessel endothelial cells via unique receptor-mediated 
transport mechanism using gp60 receptor. When gp60 is 
activated, it interacts with caveolin-1 protein, leading to 
the formation of vesicles (caveolae) which then transport 
their cargo, albumin loaded with cytotoxic agent, across the 
endothelial cells and into the tumor interstitium where it is 
trapped.
Caveolin is the principal structural protein of caveolae, 
sphingolipid, and cholesterol-rich invaginations of the plasma 
membrane involved in vesicular trafficking and signal trans-
duction.28 High expression of caveolin-1 has been associated 
with breast cancer and correlated with tumor aggressiveness 
and poor prognosis.29 The basal-like phenotype in sporadic 
and hereditary breast cancer has been associated with ele-
vated expression of caveolin, leading Roy et al to theorize 
that nab-paclitaxel may be particularly active against breast 
cancer with basal-like phenotype.30 Polyethylated castor oil 
inhibits this transport mechanism. Many tumors secrete into 
the tumor’s interstitium and onto the surface of the tumor 
cell, a protein known as secreted protein acidic and rich in 
cysteine (SPARC). As a result, the high affinity of SPARC for 
albumin is an albumin-cytotoxic uptake agent which serves to 
concentrate SPARC in the tumor. SPARC is overexpressed in 
breast cancer and has been implicated in tumor progression 
and angiogenesis.31 Nab-paclitaxel enhances tumor targeting 
through gp60 and caveolae-mediated endothelial transcytosis 
and the association with the albumin-binding protein SPARC 
in the tumor microenvironment.
Nab-paclitaxel is carried through this mechanism and can 
achieve enhanced intratumoral concentrations. Caveolin-2, 
SPARC, cortactin and dynamin 2 involved in the internaliza-
tion of albumin may also be important in determining patient 
response to nab-paclitaxel.32,33
The overexpression of human epidermal growth factor 
receptor-2 (HER2) in breast cancer has been shown to correlate 
with resistance to paclitaxel.34 To evaluate the importance of 
HER2 and SPARC status in determining the relative efficacy 
of nab-paclitaxel compared with polysorbate-based docetaxel, 
nude mice bearing six different human tumor xenografts were 
treated with nab-paclitaxel and polysorbate-based docetaxel. 
Nab-paclitaxel at submaximum-tolerated dosage was 
significantly more effective than polysorbate-based docetaxel 
at its maximum-tolerated dosage in HER2-negative tumors. 
The HER2-positive tumors had variable SPARC expression. 
In HER2-positive tumors, nab-paclitaxel was equal to or 
better than polysorbate-based docetaxel in tumors with 
medium to high SPARC levels, but not in tumors with low 
SPARC expression. These results demonstrated that the rela-
tive efficacy of nab-paclitaxel was significantly higher com-
pared with polysorbate-based docetaxel in HER2-negative 
tumors and in HER2-positive tumors with high levels of 
SPARC. The nab-paclitaxel formulation provides several 
advantages over the classical formulation of paclitaxel: 
premedication is not required because the formulation does 
not include CrEL, the intravenous infusion time of nab-
paclitaxel is shorter than CrEL-paclitaxel (30 minutes versus 
3 hours), the set of infusion equipment does not require a 
particular type of plastic structure, and the volume for the 
reconstitution of nab-paclitaxel is reduced because it can be 
reconstituted in normal saline at concentration.35
Preclinical work has demonstrated that there is preferential 
uptake of nab-paclitaxel over paclitaxel in the tumor tissue.
Desai et al reported an increased activity in terms of 
efficacy and reduced toxicity of nab-paclitaxel in five animal 
models.36 They described the plasma pharmacokinetics and 
tumor tissue/red blood cell partitioning of radiolabeled 
paclitaxel from nab-paclitaxel and placlitaxel in athymic 
mice implanted with a human breast tumor cell line. Nab-
paclitaxel partitioned rapidly into red blood cells after paren-
teral administration, and showed an enhanced biodistribution 
and prolonged half-life. The concentration of nab-paclitaxel 
in the tumor cells was 33% higher than standard paclitaxel.
Studies in vitro suggest that one mechanism for resistance 
to chemotherapy is the increased expression of vascular endo-
thelial growth factor A (VEGF-A) that is primarily respon-
sible for the vascularization of solid tumors.37,38 Paclitaxel, 
docetaxel,39 cisplatin,40 carboplatin,41 anthracyclines,42 
fluorouracil43 can induce VEGF-A expression. Chemo-
therapy-induced VEGF-A production is possibly mediated 
by mitogen-activated protein kinase/extracellular regulated 
kinase pathway, nuclear factor κB, and phosphatidylinosi-
tol 3 kinase/AKT pathway. These pathways are typically 
activated in response to stress in both tumor and endothelial 
cells. Sweeny et al showed that VEGF-A protects endothelial 
cells from the cytotoxicity effect of docetaxel.44 VEGF-A 
significantly reduces nab-paclitaxel cytotoxicity and the 
combination of bevacizumab plus nab-paclitaxel abrogates 
the VEGF-A dependent protective effect on tumor cells. OncoTargets and Therapy 2009:2 182
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Volk et al demonstrated the effectiveness of this combination 
therapy in vitro against aggressive experimental metastatic 
breast cancer.45
A variety of other drugs are being investigated, including 
oral preparations of the taxanes as well as polyglutamated 
forms of the taxanes. Any one or all of these may have their 
own particular advantages and are still in development, so 
we do not yet know whether they will receive approval, or 
how they will compare with the currently approved taxanes, 
paclitaxel and docetaxel.
Phase I studies
Ibrahim et al reported a study of dose finding with nab-
paclitaxel in 19 patients starting with a dose of 135 to 
375 mg/m2 over 30 minutes every 21 days.25 The majority 
of patients were women with breast cancer. The maximum 
dose limiting toxicity was sensory neuropathy, stomatitis, 
and superficial keratopathy. All patients received a total of 
96 cycles, and in 7 (7.3%) cycles the neutrophil count nadir 
was 500/mm3; six events occurred at the dose level above 
the maximum tolerated dose (MTD). The authors concluded 
that 300 mg/m2 is the dose to use for phase II trials. In this trial 
patients did not receive steroid and antihistamine premedica-
tion and no patients had hypersensitivity reaction.
A second trial evaluated the MTD using a weekly schedule 
of nab-paclitaxel. Dose ranged from 80 to 200 mg/m2 per 
week over 30 minutes for 3 of 4 weeks.46 The principal 
toxicity was neutropenia (grade 4) for heavily pre-treated 
patients and neuropathy (grade 3) for patients who had 
received less prior therapy. The authors suggest 150 mg/m2 
week for treatment-naive patients and 100 mg/m2 week for 
heavily pre-treated patients.
In a phase I trial, nab-paclitaxel was administered by 
intra-arterial dose at 120 to 300 mg/m2 every 3 to 4 weeks 
with an acceptable toxicity.47,48
In a trial by Gardener et al patients with malignant solid 
tumors were randomized to receive the recommended single-
agent dose of nab-paclitaxel (260 mg/m2) as a 30-minute 
infusion or as solvent-based (sb)-paclitaxel (175 mg/m2) 
as a 3-hour infusion. After cycle 1, patients crossed over to 
the alternative treatment.49 Pharmacokinetic studies were 
carried out for the first cycle of sb-paclitaxel and the first 
two cycles of nab-paclitaxel. Seventeen patients were treated, 
14 receiving at least one cycle each of nab-paclitaxel and 
sb-paclitaxel. No change in nab-paclitaxel pharmacokinetics 
was found between the first and second cycles (p = 0.95), 
suggesting limited intrasubject variability. Total drug 
exposure was comparable between the two formulations 
(p = 0.55) despite the dose difference. However, exposure 
to unbound paclitaxel was significantly higher after nab-
paclitaxel administration, due to the increased free fraction 
(0.063 ± 0.021 versus 0.024 ± 0.009; p  0.001). This study 
shows that paclitaxel disposition is subject to considerable 
variability depending on the formulation used. Because 
systemic exposure to unbound paclitaxel is likely a driving 
force behind tumoral uptake, these findings explain, at least 
in part, previous observations that the administration of nab-
paclitaxel is associated with augmented antitumor efficacy 
compared with sb-paclitaxel.
Phase II trials
Ibrahim et al treated 63 patients with breast cancer in 
a phase II trial with 300 mg/m2 of nab-paclitaxel every 
3 weeks.50 Overall objective response rate (ORR) was 
48% (95% CI 35.3%–60%); the naive patients obtained 
a 64% (95 CI: 49%–79.2%) of ORR and pre-treated 21% 
(95% CI 7.1%–42.1%). Overall median time to progres-
sion (TTP) was 26.6 months and overall survival (OS) 
was 63.6 months. The median of cycles was six; 24% of 
patients had neutropenia grade 4, 5% of whom had febrile 
neutropenia, and 11% of patients had neuropathy grade 3.
A second phase II clinical trial investigated the activity 
of nab-paclitaxel 100 mg/m2 administered days 1, 8 and 
15 every 28 days in patients with taxane-refractory meta-
static breast cancer.51 A total of 106 patients were enrolled 
and among the 66 evaluable patients, 13 (20%) had a partial 
response (PR). Seven responding patients and 3 additional 
patients with stable disease (total of 10 patients, 15%) contin-
ued abraxane for more than 24 weeks. Grade 4 toxicity was 
neutropenia, occurring in 5 (8%) patients. Other toxicities 
(grade 2–3) included: nausea, infection, fatigue, vomiting, 
neuropathy, constipation, diarrhea, edema and mucositis.
Roy et al studied weekly nab-paclitaxel and gemcitabine 
combination in a phase II trial in patients with previously 
untreated metastatic breast cancer.30 Nab-paclitaxel (125 mg/m2) 
and gemcitabine (1000 mg/m2) were administered on days 1 
and 8 every 21 days until disease progression. Of 50 treated 
patients, 40 (80%) had visceral organ involvement and 
30 (60%) had 3 or more sites of metastases. Four (8%) 
and 21 (42%) patients had complete response and PR by 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria. Median duration of response was 6.9 months 
(95% CI 5.7, not reached), median progression-free survival 
(PFS) 7.9 months (95% CI 5.4–10 months), and median OS 
was not reached. PFS and OS at 6 months were 60% (95% 
CI 48%–76%) and 92% (95% CI 85%–100%), respectively. OncoTargets and Therapy 2009:2 183
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Most frequent grade 3–4 toxicity included neutropenia 
(52%), fatigue (28%), anemia (14%), dyspnea (14%), and 
thrombocytopenia (12%).
An unplanned subgroup analysis of triple-negative 
patients in this trial reported that 10 of 13 (77%) of patients 
(95% CI 46%–95%) had response compared with 16 of 
36 other patients (44%, 95% CI 28%–62%). These data 
suggest the possibility that basal-like breast cancer could be 
particularly responsive to the nab-paclitaxel regimen. In this 
trial, treatment was well tolerated. Neutropenia was the most 
common toxicity (grades 3–4 neutropenia: 43% and 12%), 
only one patient developing febrile neutropenia.
Link et al reviewed, in a retrospective analysis, 40 women 
with breast cancer treated with a combination of nab-
paclitaxel plus bevacizumab for a minimum of 2 courses.52 
Of 33 women with measurable disease, 16 (48%) had ORR 
to the nab-paclitaxel/bevacizumab regimen (3 complete 
response [CR] and 13 PRs). Median TTP for responders was 
128 days and 135 days for the 15% of patients with stable 
disease (SD). Another 5 women had stable disease with a 
median duration of 135 days. Of 7 patients with bone-only 
disease, 2 had almost complete resolution of PET activity 
and 4 had SD (median, 148 days). Toxicity was acceptable, 
fatigue, neuropathy, pain, and hypertension being the most 
common complaints. In conclusion, this trial suggests a 
better outcome for patients treated with a weekly schedule 
(ORR + SD: 73.7% versus 50%) than those on the 3-week 
treatment regimen. In Table 1 the ORR is reported based 
on tumor cell characteristics.52,53
An ongoing phase II trial, with nab-paclitaxel plus 
bevacizumab as first-line therapy for patients with breast 
cancer and Her-2 negative, showed no statistically or clini-
cally significant differences in rates of grade 3–4 toxicities. 
This trial compared nab-paclitaxel 260 mg/m2 every 3 weeks 
to nab-paclitaxel 260 mg/m2 every 2 weeks plus filgrastim 
or nab-paclitaxel 130 mg/m2 weekly.54
Blum et al treated patients with metastatic breast cancer 
with weekly nab-paclitaxel.55 Women with metastatic 
breast cancer who were previously treated with taxanes 
were eligible for participation. Taxane failure was defined 
as metastatic disease progression during taxane therapy or 
relapse within 12 months of adjuvant taxane therapy. Primary 
objectives were ORR and toxicity. Women were treated 
with nab-paclitaxel 100 mg/m2 (n = 106) or 125 mg/m2 
(n = 75) on days 1, 8, and 15 of a 28-day cycle. ORR were 
14% and 16% for the 100 mg/m2 and 125 mg/m2 cohorts, 
respectively; an additional 12% and 21% of patients, respec-
tively, had stable disease for 16 weeks or more. Median PFS 
was 3 months at 100 mg/m2 and 3.5 months at 125 mg/m2; 
median survival times were 9.2 months and 9.1 months, 
respectively. Survival was similar for responding patients 
and those with SD. No severe hypersensitivity reactions were 
reported. Patients who developed treatment-limiting periph-
eral neuropathy typically could be restarted on a reduced 
dose of nab-paclitaxel after a 1- to 2-week delay. Grade 4 
neutropenia occurred in 5% of patients.
The combination of nab-paclitaxel and capecitabine was 
evaluated in patients with breast cancer.56 Preliminary data 
from an ongoing phase II study evaluated 50 treatment-naive 
patients with breast cancer using capecitabine (825 mg/m2 
twice daily on days 1 to 14) plus nab-paclitaxel (125 mg/m2 
admistered on days 1 and 8) every 3 weeks. ORR was 47.5%, 
complete response (CR) 8% in 38 evaluable patients, and SD 
in 39.4%. Principal toxicity grade 3–4 was fatigue, hand-foot 
syndrome, febrile neutropenia or neutropenia alone.
Phase III trials
A randomized trial compared in 460 breast cancer patients a 
classical schedule of paclitaxel (175 mg/m2 in 3 hours) versus 
nab-paclitaxel (260 mg/m2 over 30 minutes) every 3 weeks.57 
In the arm with CrEL paclitaxel all patients received premedi-
cation with corticosteroid and antihistamines. Of all patients, 
Table 1 response rate and tumor cell characteristics of ABC treated with bevacizumab plus nab-paclitaxel52,53
Response
  Total patients CR (n) ORR (%) SD (n) CB (%) PD
er-pos or Pgr-pos 23 1 43.5% 4 60.9% 9
er-neg or Pgr-neg 10 2 60% 1 70% 3
Her-2-neg 21 2 47.6% 1 52.4% 10
Her-2-pos 12 1 50.% 4 83.3% 2
Triple neg 4 1 75% 0 75% 1
Total 33 3 48.5% 5 63.9% 12
Abbreviations: Cr, complete response; Orr, overall response rate; PD, progressive disease; SD, stable disease; Pgr, progesterone receptor; er, estrogen receptor; CB, 
clinical benefit.OncoTargets and Therapy 2009:2 184
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76% had more than three metastatic lesions and 79 patients 
had visceral disease. Of 460 patients, 86% were pre-treated 
with previous chemotherapy and 77% versus 78% of random-
ized patients had chemotherapy including anthracycline, in 
nab-paclitaxel and paclitaxel respectively. In the arm with 
nab-paclitaxel, ORR was significantly higher than with 
standard paclitaxel (33% versus 19%; p = 0.001) and TTP 
was significantly longer (23.0 versus 16.9 weeks; hazard 
ratio = 0.75; p = 0.006), respectively. The ORR in the 
97 treatment-naive patients was 42% in the nab-paclitaxel 
arm and 27% in the standard paclitaxel arm. When the 
patients were pre-treated with anthracyclines (adjuvant plus 
advanced), ORR was 34% and 18%, respectively. In the 
nab-paclitaxel arm, patients received an average paclitaxel 
dose intensity 49% greater than patients in the standard 
paclitaxel arm. The incidence of hypersensitivity reactions 
(any grade) was low in both arms (nab-paclitaxel 1% and 
CrELpaclitaxel 2%). No patients in the experimental arm 
received premedication with steroids and antihistamines, 
but in 8% of patients steroids were administered for emesis, 
myalgia/arthralgia, or anorexia. The most frequent toxicities 
were alopecia, sensory neuropathy, fatigue, neutropenia, 
arthralgia/myalgia, nausea and diarrhea (Table 2).
Neutropenia grade 4 was significantly lower in the 
nab-paclitaxel arm (9% versus 22%) with a higher mean 
neutrophil nadir. These data suggest that CrEL can contribute 
to this toxicity. Febrile neutropenia was uncommon (2%) 
in both study arms. Eight patients (3%) in the nab-paclitaxel 
group and 14 patients (6%) in the standard paclitaxel group 
received growth factor treatment for neutropenia during the 
study, without any toxic deaths. Peripheral neurotoxicity 
was more frequent in the experimental arm (10% versus 2%; 
p  0.001) because this group of patients received a higher 
dose of paclitaxel. No episodes of motor neuropathy or grade 
4 sensory neuropathy were reported in either group. The 
researchers managed this toxicity by a reduction in dose and 
treatment interruption. In the arm with standard paclitaxel 
7% of patients had higher serum glucose level than in the 
nab-paclitaxel arm (1%; p = 0.003). The analyses of toxicity 
in patients over 65 years of age indicate that principal adverse 
events were notably lower in the nab-paclitaxel group, with-
out any additional difference between older and younger 
patients (Table 3). Analyses of quality of life showed no 
difference despite the higher dose administered in the nab-
paclitaxel group. This trial shows that with a new formula-
tion of paclitaxel it is possible to deliver a higher dose of 
paclitaxel. ORR, TTP, and toxicity were significantly better 
with nab-paclitaxel than CrEl paclitaxel. These results were 
more evident in treatment-naive patients.
A randomized study evaluated the weekly schedule 
versus every-3-weeks schedule of nab-pacliatxel versus 
docetaxel in 302 patients with naive breast cancer.58 The 
primary end-point of this trial was ORR. Preliminary results 
(interim analysis) revealed that ORR in the every-3-weeks 
schedule of nab-paclitaxel and docetaxel were compa-
rable (33 versus 36%), while ORR in the weekly docetaxel 
schedule (100 and 150 mg/m2) was higher than with the 
every-3-weeks schedule (58% versus 36%, p = 0.004; 62% 
versus 36%, p = 0.016). There was no difference between 
the two schedules of nab-paclitaxel (p = 0.424), while ORR 
in the weekly schedule was higher than with the 3-week 
schedule of nab-paclitaxel. Grade 4 neutropenia and febrile 
neutropenia were less frequent with nab-paclitaxel than with 
docetaxel. Peripheral neuropathy was 5% in the docetaxel 
arm and 14% in the nab-paclitaxel arm every 3 weeks, and 
7% and 12%, respectively, in the weekly schedule. This trial 
suggests that the weekly schedule of nab-paclitaxel is more 
effective than every 3 weeks in metastatic breast cancer 
(Table 4 and 5).
Table 2 Adverse events (all grades) reported in either group
Adverse events Nab-paclitaxel CrEL paclitaxel p
  % of pts % of pts  
Alopecia 90 93
Sensory  
neuropathy
70 55 0.001
Fatigue 45 35
Neutropenia 30 50
Arthralgia 30 29
Myalgia 25 28
Nausea 27 20
Diarrhea 23 15
Hyperglycemia 1 7 0.003
Hypersensitivity  
reactions
1 2
Table 3 Adverse events in patients 65 years old in the 
nab-paclitaxel group compared with the CreL-paclitaxel group
Adverse events Nab-paclitaxel CrEL paclitaxel
  % of pts % of pts
Neutropenia 23 59
Leukopenia 10 31
Nausea 20 38
Hyperglycemya 0 19
Flushing 0 16OncoTargets and Therapy 2009:2 185
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For these drugs, the substantially lower neuropathy that 
improved rapidly (median 22 days), no need for premedica-
tion, and less myelosuppression should be highlighted. Then, 
of course, the next step is to see where these drugs fit into 
adjuvant therapy for the advanced stage setting.
An economic analysis comparing nab-paclitaxel and 
docetaxel, both as alternatives to paclitaxel in metastatic 
breast cancer, was conducted.59 The clinical and safety data 
were obtained from a meta-analysis of randomized trials 
comparing either nab-paclitaxel (260 mg/m2 every 3 weeks) 
or docetaxel (100 mg/m2) every 3 weeks, with standard 
paclitaxel (175 mg/m2) every 3 weeks. Nab-paclitaxel had 
the lowest incidence of grade 3–4 toxicity. This translated 
to lower overall costs for managing the grade 3–4 events 
relative to both docetaxel and paclitaxel (US$597 versus 
US$2626 versus US$1227). Using the median number of 
cycles administered and the cost effect of grade III/IV toxic-
ity, the overall cost for nab-paclitaxel would be US$15,105 
compared to US$15,268 for docetaxel and US$3557 for 
paclitaxel. When treatment preferences were assessed, 
20 of 24 (83.3%) respondents selected nab-paclitaxel as 
their preferred choice compared to only 4 who selected 
docetaxel. These corresponded to a gain of 0.203 and 0.016 
quality adjusted life years (QALYs) for nab-paclitaxel and 
docetaxel, respectively. With these utility benefits, the incre-
mental cost per QALY gained was more favorable for nab-
paclitaxel than docetaxel (US$56,800 versus US$739,600). 
Nab-paclitaxel would be an economically reasonable alter-
native to docetaxel in metastatic breast cancer patients. The 
US Food and Drug administration approved nab-paclitaxel 
Table 4 Summary of phase ii clinical studies of novel taxane formulations
Author Regimen No. patients Outcome Toxicity
RR% TTP (mos) PFS% MS OS Grade 3–4 (%)
ibrahim et al50 Nab-paclitaxel300 mg/m2 q3w 63 48 26,6 63,6 Neutropenia g4 (24)   
Neuropathy g3 (11)
Blum et al51 Nab-paclitaxel 100 mg/m2 w 66 20 (rP) Neutropenia g4 (8) 
Nausea g4 (4,5) 
infection g4 (4,5)
roy et al30 Nab-paclitaxel 125 mg/m2 w + 
Gemcitabine 1000 mg/m2 w
50 50 60 92 Neutropenia g4 (12) 
Neutropenia g3 (43)
Link et al52 Nab-paclitaxel plus Bevacizumab 40 48,5 4,2
Blum et al55 Nab-paclitaxel 100 mg/m2 w 181 14 3 9,2 Neutropenia g4 (5)
Nab-paclitaxel 125 mg/m2 w 16 3,5 9,1
Schwartzberg et al56 Nab-paclitaxel 125 mg/m2 w + 
Capecitabine 825 mg/m2
50 47,5         Neutropenia g4 (20) 
Fatigue g4 (20)
Abbreviations:  TTP, time to progression; MS, median survival; OS overall survival; PFS, progression free survival; rr, response rate; q3w, every 3 weeks; mos, months; w, week; 
MS, median survival.
Table 5 Summary of phase iii clinical studies of novel taxane formulations
Author Regimen No. patients Outcome Toxicity
      RR% TTP (mos) PFS (mos) Grade 3–4 (%)
Gradishar et al57 Nab-paclitaxel 260 mg/m2 q3w 
vs 
Paclitaxel 175 mg/m2 q3w
229 
 
225
33 
 
19
23 
 
16,9
25,7 
 
25,2
Neutropenia g4 (9) 
Neuropathy g3 (10) 
Neutropenia g4 (22) 
Neuropathy g3 (2)
Gradishar et al58 
 
 
 
 
 
Nab-paclitaxel 300 mg/m2 q3w 
vs 
Nab-paclitaxel 100 mg/m2 q3/4w 
vs 
Nab-paclitaxel 150 mg/m2 q3/4w 
vs 
Docetaxel 100 mg/m2 q3/4w
76 
 
76 
 
74 
 
74
33 
 
58 
 
62 
 
36
 
 
 
 
 
 
10,6 
 
9,3 
 
9,2 
 
7,3
Neutropenia g4 (4) 
Neuropathy g3 (14) 
Neutropenia g4 (3) 
Neuropathy g3 (7) 
Neutropenia g4 (7) 
Neuropathy g3 (12) 
Neutropenia g4 (74)
Abbreviations:   TTP, time to progression; PFS, progression free survival; rr, response rate; q3w, every 3 weeks; mos, months; w, week; MS, median survival; q3w, every 3 weeks; 
q3/4 w, every 3 or 4 weeks; mos, months; w, week.OncoTargets and Therapy 2009:2 186
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for the treatment of metastatic breast cancer after failure of 
combination chemotherapy or relapse after adjuvant therapy 
within 6 months.
Neoadjuvant chemotherapy
Preliminary studies have also evaluated nab-paclitaxel in 
neoadjuvant treatment of breast cancer. Sixty-six women 
with locally advanced breast cancer received neoadjuvant 
chemotherapy with 5-fluorouracil (500 mg/m2), epirubicin 
(100 mg/m2) plus cyclophosphamide (500 mg/m2) every 
3 weeks and trastuzumab for HER-2 positive patients.60 All 
patients received 4 cycles of chemotherapy. CR was 32% 
(95% CI, 21%–45%) with nab-paclitaxel in patients with 
HER-2 negative hormone receptor negative breast cancer, 
the CR was 29%, while 59% in patients HER-2 positive 
hormone receptor negative breast cancer.
Somlo et al evaluated a neoadjuvant phase II trial in 
patients with stage 3–4 or inflammatory breast cancer.61 
All patients received 6 cycles of docetaxel (75 mg/m2), 
doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) 
(TAC schedule), or doxorubicin (600 mg/m2) and cyclo-
phosphamide (600 mg/m2) administered every 2 weeks for 
4 cycles followed by carboplatin (AUC-2) and nab-paclitaxel 
(100 mg/m2) given every 4 weeks for 3 cycles (ACAC 
schedule).
Patients with HER-2 positive breast cancer received 
ACAC plus trastuzumab. In the TAC schedule, 7% of patients 
obtained CR, 5% in the ACAC schedule and 40% in the 
HER-2 positive patients (ACAC-T).
In the ACAC schedule, 7% of 14 patients obtained 
pathological CR and 23% minimal residual cancer burden 
(RCB), as in the TAC schedule arm, compared with 40% 
(CR) and 0% (RCB) of 10 patients treated with ACAC-T 
and TAC, respectively.
Principal toxicities included neuropathy, neutropenia, 
febrile neutropenia, trombocitopenia, anemia, fatigue, 
gastrointestinal toxicities, while the highest rate of grade 4 
neutropenia occurred in the TAC schedule.
Daniel et al treated 72 women with breast cancer with 
gemcitabine (2000 mg/m2), epirubicin (50 mg/m2) and 
nab-paclitaxel (175 mg/ m2) every 2 weeks for 6 cycles as 
neoadjuvant treatment.62 Of 35 patients evaluable for response, 
20% had pathological CR and 74% PR, while 6% had SD.
Neutropenia grade 3–4 was 8%, thrombocytopenia 6%, 
without febrile neutropenia or grade 3–4 neuropathy. Trials 
with the combination including nab-paclitaxel as adjuvant 
therapy for breast cancer are ongoing and preliminary results 
are promising.
Conclusions
Clinical studies have shown that nab-paclitaxel has sub-
stantial activity and manageable toxicity as chemotherapy 
for breast cancer, and the outcome is better than with pacli-
taxel formulated with CrEL, with almost double the ORR, 
increased TTP and increased survival in second-line patients. 
The nab formulation is associated with decreased neutropenia 
and rapid improvement of peripheral neuropathy compared 
with CrEL-paclitaxel. For these reasons, nab-paclitaxel can 
be administered by using higher doses of paclitaxel than 
those achievable with CrEL-paclitaxel, with shorter infu-
sion duration and without a mandatory premedication with 
corticosteroids and antihistamines to reduce the risk of sol-
vent-mediated hypersensitivity reactions. Nab technology has 
increased the therapeutic index of paclitaxel in breast cancer 
compared with the conventional solvent-based formulations. 
Further randomized trials in advanced and adjuvant treatment 
of breast cancer using nab-paclitaxel in combination with 
other drugs are needed.
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